SUBSCRIBE
SUBSCRIBE
News   FDA

U.S. Clears New Version of Novo Nordisk, Inc. Clot Therapy

May 12, 2008 | 
1 min read
WASHINGTON (Reuters) - Denmark's Novo Nordisk won U.S. approval to sell a new formulation of a genetically engineered protein therapy that helps the blood clot, regulators said on Friday.
FDA Approvals
MORE ON THIS TOPIC
Podcast
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
November 4, 2026
 · 
1 min read
 · 
Jef Akst
Zigzag upward arrow chart, financial progress, market growth,
Psychedelics
Compass to submit psilocybin depression drug for approval imminently after stock wobbles
November 3, 2026
 · 
2 min read
 · 
Heather McKenzie
Light at the end of railroad tunnel. Natural lighting.
FDA
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
November 2, 2026
 · 
2 min read
 · 
Heather McKenzie
vision for success ideas. businessman's perspective for future planning. Silhouette of man holding binoculars on mountain peak against bright sunlight sky background.
FDA
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
November 2, 2026
 · 
6 min read
 · 
Heather McKenzie